About MicuRx
Our company
Our Team
Vision & mission
History
Contact Us
Scientific research
Antibiotic Resistance
Kidney Disease
MicuRx R&D
Publications
Pipeline
Newsroom
Corporate news
Careers
Contact Us
中
Selection and characterization of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I
Time:2014-05-13 / View:565 times
Prev:
In vivo Antibacterial Activity of MRX-I, a New Oxazolidinone
Next:
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile
Back
Close